Neurogranin-Guided Synapse Rescue Therapy

Migration, Crosslink

📖

Neurogranin-Guided Synapse Rescue Therapy

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-biomarker-neurogranin-synapse

📖 Wiki Page

idea2006 wordssynced 2026-04-02

Neurogranin-Guided Synapse Rescue Therapy

Executive Summary

Therapy Concept: Neurogranin-Guided Synapse Rescue Score: 78/100 (Biomarker-Driven Therapy) Target: Synaptic integrity restoration in neurodegenerative diseases Primary Indication: Alzheimer's Disease, with applications in Alzheimer's Disease, Parkinson's Disease Dementia, and Frontotemporal Dementia

This evidence synthesis reviews the scientific foundation for using neurogranin (Ng) as both a biomarker for synaptic health and a therapeutic target for synapse rescue interventions. Neurogranin offers a unique opportunity to directly target synaptic loss—the strongest correlate of cognitive impairment in neurodegenerative diseases—rather than focusing solely on pathological protein clearance.

Neurogranin Biology and Synaptic Function

Molecular Mechanism

Neurogranin (RC3/Ng) is a 78-amino acid postsynaptic neuronal protein enriched in [dendritic spines](/cell-types/neurons) of excitatory [neurons](/entities/neurons) in the [hippocampus](/brain-regions/hippocampus) and cerebral [cortex](/brain-regions/cortex)[@dekker2020][@zhang2021]. It serves as a critical regulator of synaptic plasticity through multiple mechanisms:

...

Neurogranin-Guided Synapse Rescue Therapy

Executive Summary

Therapy Concept: Neurogranin-Guided Synapse Rescue Score: 78/100 (Biomarker-Driven Therapy) Target: Synaptic integrity restoration in neurodegenerative diseases Primary Indication: Alzheimer's Disease, with applications in Alzheimer's Disease, Parkinson's Disease Dementia, and Frontotemporal Dementia

This evidence synthesis reviews the scientific foundation for using neurogranin (Ng) as both a biomarker for synaptic health and a therapeutic target for synapse rescue interventions. Neurogranin offers a unique opportunity to directly target synaptic loss—the strongest correlate of cognitive impairment in neurodegenerative diseases—rather than focusing solely on pathological protein clearance.

Neurogranin Biology and Synaptic Function

Molecular Mechanism

Neurogranin (RC3/Ng) is a 78-amino acid postsynaptic neuronal protein enriched in [dendritic spines](/cell-types/neurons) of excitatory [neurons](/entities/neurons) in the [hippocampus](/brain-regions/hippocampus) and cerebral [cortex](/brain-regions/cortex)[@dekker2020][@zhang2021]. It serves as a critical regulator of synaptic plasticity through multiple mechanisms:

Calmodulin Buffering: Ng binds to calmodulin in the absence of calcium, regulating calmodulin availability for downstream signaling cascades[@gerhard2019]

[LTP](/mechanisms/long-term-potentiation) Induction: Required for [long-term potentiation](/mechanisms/synaptic-plasticity) in hippocampal neurons through PKC-dependent phosphorylation[@li2020]

Dendritic Spine Morphogenesis: Controls spine formation, maintenance, and structural plasticity[@wang2018]

[NMDA Receptor](/entities/nmda-receptor) Signaling: Modulates NMDA receptor-dependent signaling and synaptic strength[@huang2021]

Expression Patterns

| Brain Region | Expression Level | Clinical Relevance |
|-------------|------------------|-------------------|
| Hippocampus (CA1) | Highest | Memory formation, early AD vulnerability |
| Cortex (Layer II-III) | High | Executive function, cognitive processing |
| Striatum | Moderate | Motor learning, PD relevance |
| Basal Forebrain | Moderate | Cholinergic modulation |

Neurogranin as Biomarker for Synaptic Health

Cerebrospinal Fluid Biomarker

Multiple studies have validated CSF neurogranin as a sensitive marker of synaptic dysfunction[@kester2019][@tarawneh2020][@wellington2020]:

Alzheimer's Disease: CSF Ng elevated 2-3x compared to healthy controls
MCI due to AD: Moderately elevated, predicts progression to AD dementia
Disease Progression: Levels correlate with cognitive decline rate
Diagnostic Specificity: Helps differentiate AD from other dementias

Plasma Neurogranin

Recent advances in ultra-sensitive assays (Simoa) enable plasma neurogranin detection[@ashton2021][@karikari2020]:

Correlates with CSF levels
Associates with cognitive performance
Potential for minimally invasive monitoring

Comparison with Other Synaptic Biomarkers

| Biomarker | Sample | Specificity | Clinical Utility |
|-----------|--------|-------------|-----------------|
| Neurogranin | CSF/Plasma | Synaptic spines | AD progression |
| SNAP-25 | CSF | Presynaptic terminal | Motor neuron disease |
| Synaptotagmin-1 | CSF | Synaptic vesicles | Broad neurodegeneration |
| Synaptophysin | CSF/ tissue | Presynaptic vesicles | Post-mortem diagnosis |

Synaptic Rescue Mechanism Evidence

Therapeutic Rationale

The synapse rescue approach is grounded in the observation that synaptic loss—rather than amyloid or [tau](/proteins/tau) pathology alone—best correlates with cognitive impairment in AD[@selkoe2002][@savage2018]. Neurogranin-based interventions aim to:

Preserve Existing Synapses: Protect [dendritic spines](/cell-types/dendritic-spines) from degeneration

Promote Synaptogenesis: Stimulate new synapse formation

Restore Synaptic Function: Enhance [LTP](/mechanisms/long-term-potentiation) and synaptic plasticity

Modulate Calcium Signaling: Normalize calmodulin-dependent cascades

Preclinical Evidence

Several therapeutic strategies show promise in preclinical models[@sun2019][@nelson2020][@kim2021]:

PKC Activators: Enhance neurogranin phosphorylation and synaptic plasticity
Calmodulin Stabilizers: Improve calcium signaling at synapses
NMDA Receptor Modulators: Enhance neurogranin-dependent LTP
Neurotrophic Factors: BDNF and related compounds promote neurogranin expression

Intervention Candidates and Evidence Levels

Tier 1: High Evidence Interventions

| Intervention | Mechanism | Evidence Level | Development Stage |
|-------------|-----------|----------------|-------------------|
| PKC activators (e.g., Bryostatin) | Enhance Ng phosphorylation | Tier 1 | Phase 2 clinical trials |
| NMDA partial agonists | Enhance LTP | Tier 1 | Preclinical/Phase 1 |
| Calcium stabilizers | Normalize CaM signaling | Tier 1 | Preclinical |

Tier 2: Moderate Evidence Interventions

| Intervention | Mechanism | Evidence Level | Development Stage |
|-------------|-----------|----------------|-------------------|
| BDNF mimetics | Increase Ng expression | Tier 2 | Preclinical |
| AMPK activators | Promote synaptic plasticity | Tier 2 | Research |
| Antioxidants | Protect spines from oxidative stress | Tier 2 | Preclinical |

Tier 3: Emerging Strategies

| Intervention | Mechanism | Evidence Level | Development Stage |
|-------------|-----------|----------------|-------------------|
| Gene therapy (NRGN) | Restore Ng expression | Tier 3 | Preclinical |
| Ng fragments (therapeutic) | Mimic Ng function | Tier 3 | Discovery |
| Antibody-based therapies | Target Ng pathways | Tier 3 | Discovery |

Implementation Roadmap

Phase 1: Biomarker Validation (12 months)

Standardize CSF/plasma Ng assay
Establish reference ranges
Validate in multi-center cohort
Estimated Cost: $2-3M

Phase 2: Target Validation (18 months)

Identify patient subgroups with elevated Ng
Correlate Ng with imaging biomarkers
Establish therapeutic window
Estimated Cost: $5-8M

Phase 3: Clinical Trials (24-36 months)

Select lead intervention
Design biomarker-enriched trial
Implement adaptive design
Estimated Cost: $15-25M per indication

Phase 4: Commercialization (12 months)

CDx development
Regulatory submission
Market access
Estimated Cost: $3-5M

Rubric Scoring (10 Dimensions)

| Dimension | Score (0-10) | Rationale |
|-----------|-------------|-----------|
| Biological Plausibility | 9 | Strong mechanistic link to synaptic function |
| Biomarker Validation | 9 | Extensively validated in multiple cohorts |
| Preclinical Evidence | 7 | Moderate evidence in animal models |
| Clinical Feasibility | 8 | Assay technology available, minimally invasive |
| Target Accessibility | 7 | Brain-penetrant small molecules achievable |
| Competitive Landscape | 8 | Limited direct competitors |
| Regulatory Pathway | 7 | Biomarker-first approach de-risks development |
| Commercial Potential | 8 | Large addressable market |
| Patient Selection | 9 | Ng enables precise patient stratification |
| Combination Potential | 8 | Synergizes with anti-amyloid/tau therapies |

Total Score: 78/100

Strategic Advantages

Differentiated Mechanism

Unlike amyloid-targeted therapies ([lecanemab](/entities/lecanemab), donanemab) or tau-targeted approaches, neurogranin-guided therapy directly addresses synaptic integrity—the final common pathway for cognitive impairment[@long2023][@van2023].

Combination Therapy Potential

Ng-based interventions may synergize with:

Anti-amyloid antibodies (reduce excitotoxic stress)
Anti-tau therapies (preserve microtubule function)
Neurotrophic factors (enhance synaptic plasticity)

Companion Diagnostic

Neurogranin levels enable:

Patient stratification for clinical trials
Treatment response monitoring
Disease progression tracking

Risk Assessment

Technical Risks

| Risk | Likelihood | Mitigation |
|------|------------|-----------|
| Insufficient brain penetration | Medium | Focus on [BBB](/entities/blood-brain-barrier)-penetrant PKC activators |
| Off-target effects | Medium | Develop targeted delivery systems |
| Biomarker variability | Low | Standardize assay protocols |

Commercial Risks

| Risk | Likelihood | Mitigation |
|------|------------|-----------|
| Competition from existing therapies | Low | First-mover in synapse rescue |
| Regulatory hurdles | Medium | Biomarker-first approach |
| Reimbursement challenges | Medium | Demonstrate clinical utility |

Overview

Mermaid diagram (expand to render)

This idea describes a therapeutic approach targeting neurogranin as a biomarker for synapse rescue in neurodegenerative diseases. Neurogranin is a postsynaptic protein that plays a critical role in synaptic plasticity and cognitive function.

External Links

[Neurogranin Research](https://pubmed.ncbi.nlm.nih.gov/)
[Clinical Trials](https://clinicaltrials.gov)

Actionable Next Steps

Lab Experiments

Neurogranin assay standardization: Establish reference ranges for plasma neurogranin using Simoa (Quanterix) vs. ELISA (Euroimmun) in 500+ samples from AD, PD, FTD, and healthy controls

Synaptic density readouts: Develop correlative assays linking CSF neurogranin to synaptic density measures (PET TSPO, SV2A PET) in human subjects

Therapeutic target validation: Test whether synaptoprotective compounds (BDNF analogs, NMDA modulators, AMPAR positive allosteric modulators) reduce CSF neurogranin in iPSC-derived neuron models

Clinical Protocol Design

Synaptic rescue enrichment trial: Design Phase 2 trial using CSF Ng >80 pg/mL as enrollment criterion to select patients with active synaptic loss

Combinatorial approach: Pair synapse-rescue candidates (e.g., AmpaKine CX516, BDNF mimetics) with anti-amyloid or anti-tau therapy; use Ng as response biomarker

Adaptive design: Interim analysis at 24 weeks; if Ng not declining, add or switch to alternative mechanism

Cognitive co-primary: Include both cognitive endpoint (ADAS-Cog13) and synaptic biomarker (CSF Ng change) as co-primary

Company Partnership Opportunities

Synapse-targeted therapeutics:

AC Immune — tau/alpha-syn immunotherapies with synaptic protection
Roche/Genentech — neuroscience pipeline including synaptic modulators
Eli Lilly — BDNF pathway investments

2. Biomarker companies:

Quanterix — Simoa neurogranin assay
Euroimmun — Neurogranin ELISA
C2N Diagnostics — multi- biomarker panels

3. Digital cognitive: Cambridge Cognition, Cognivive for cognitive endpointreadouts

Grant Targets

NIH NIA:

R01: "Neurogranin-guided synapse rescue in early AD" (~$1.5M over 5 years)
U01 (clinical trial): "Synaptic Biomarker-Enabled Precision Therapy for AD"
ADRC biomarker cores — integrate Ng into standard assessment batteries

2. Foundations:

BrightFocus — A2022012N (synaptic dysfunction in AD)
Alzheimer's Association — Zenith Fellowship for early-stage investigators
Michael J. Fox Foundation — Ng as synaptic marker in PD progression

3. Industry-academic:

NIH Blueprint Neurotherapeutics Network
European Innovative Medicines Initiative (IMI) — NEURONET

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7/10/10 | Neurogranin as biomarker is established; therapeutic targeting emerging |
| Mechanistic Rationale | 7/10/10 | Neurogranin modulates synaptic plasticity; restoration enhances cognition |
| Addresses Root Cause | 7/10/10 | Addresses synaptic dysfunction - core pathological feature |
| Delivery Feasibility | 6/10/10 | Peptide or small molecule approaches; brain delivery needed |
| Safety Plausibility | 7/10/10 | Endogenous protein; good safety profile expected |
| Combinability | 8/10/10 | Excellent combination with other synaptic and cognitive enhancers |
| Biomarker Availability | 8/10/10 | Neurogranin in CSF well-validated biomarker; easily measurable |
| De-risking Path | 6/10/10 | Preclinical stage; biomarker enables patient selection |
| Multi-disease Potential | 7/10/10 | Relevant for AD, PD, schizophrenia, cognitive aging |
| Patient Impact | 8/10/10 | Could restore cognitive function by enhancing synaptic plasticity |
| Total | 71/100 | |

[Neurogranin (Ng) - Synaptic Biomarker](/proteins/neurogranin-protein)
[Neurogranin (RC3) Protein](/proteins/neurogranin-protein)
NRGN Gene
[Synaptic Plasticity](/mechanisms/synaptic-plasticity)
[Long-Term Potentiation](/mechanisms/synaptic-dysfunction)
[Alzheimer's Disease Biomarkers](/diseases/alzheimers-disease#biomarkers)

Cross-Links

Diseases

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Parkinson's Disease Dementia](/diseases/parkinsons-disease-dementia)
[MCI](/diseases/mild-cognitive-impairment)
[Neurodegeneration](/diseases/neurodegeneration)

Mechanisms

[Synaptic Plasticity](/mechanisms/synaptic-plasticity)
[Long-Term Potentiation](/mechanisms/synaptic-dysfunction)
Synapse Formation
Calmodulin Signaling
NMDA Receptor Signaling
PKC Signaling
[Dendritic Spine Morphogenesis](/genes)

Proteins & Genes

[Neurogranin](/proteins/neurogranin-protein)
RC3
Calmodulin
[NMDA Receptor](/entities/nmda-receptor)
[AMPA Receptor](/proteins/ampa-receptor)
[PKC](/genes/pkc)
CaMKII

Cell Types

[Neurons](/cell-types/neurons)
[Hippocampal Neurons](/cell-types/hippocampal-neurons)
[Cortical Neurons](/cell-types/cortical-neurons)
[Dendritic Spines](/mechanisms/dendritic-spines)
Synapses

Brain Regions

[Hippocampus](/brain-regions/hippocampus)
[Cortex](/brain-regions/cortex)
CA1
[Striatum](/brain-regions/striatum)
[Basal Forebrain](/brain-regions/basal-forebrain)

Treatments

[Biomarker-Guided Therapy](/biomarkers)
Synaptic Therapy
[Small Molecule Therapy](/therapeutics)
[Gene Therapy](/technologies/gene-therapy)
Protein Therapy

Additional Topics

[CSF Biomarkers](/biomarkers)
Synaptic Health
Cognitive Function
Memory Formation

References

[Dekker et al., Neurogranin as a synaptic biomarker in AD (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32967000/)

[Zhang et al., Neurogranin structure and function (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33555510/)

[Gerhard et al., Calmodulin binding to neurogranin (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31140567/)

[Li et al., Neurogranin and LTP (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32083742/)

[Wang et al., Dendritic spine regulation by neurogranin (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29485712/)

[Huang et al., NMDA receptor and neurogranin signaling (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34044556/)

[Kester et al., CSF neurogranin as AD biomarker (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30681787/)

[Tarawneh et al., Neurogranin and cognitive decline (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32489043/)

[Wellington et al., Diagnostic utility of CSF neurogranin (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32861234/)

[Ashton et al., Plasma neurogranin in AD (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33872665/)

[Karikari et al., Ultra-sensitive neurogranin assay (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32735318/)

[Unknown, Selkoe, Synaptic failure in AD (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12498825/)

[Savage et al., Synaptic loss correlates with cognition (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29439479/)

[Sun et al., PKC activators and synaptic plasticity (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31305982/)

[Nelson et al., BDNF and neurogranin expression (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32018347/)

[Kim et al., Neuroprotective strategies targeting Ng (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/33998012/)

[Long et al., Lecanemab Phase 3 CLARITY (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38156552/)

[van Dyck et al., Donanemab TRAILBLAZER-ALZ 2 (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37450147/)

[Mattson et al., Calcium signaling in neuronal death (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10774722/)

[Bredt et al., NMDA receptor regulation (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11292642/)

[Hering et al., Dendritic spine changes in AD (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28379475/)

[Penzes et al., Dendritic spine remodeling in AD (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21720152/)

[Spires-Jones et al., Synapses and AD (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26972641/)

[Cissé et al., Synaptic activity in AD (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21849485/)

[Querfurth et al., BDNF and synaptic plasticity (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20374720/)

[Unknown, Luine et al.,Estradiol and synaptic plasticity (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19153601/)

[Woolf et al., Neurogranin in psychiatric disorders (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11431223/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Neurogranin-Guided Synapse Rescue Therapy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ideas-biomarker-neurogranin-synapse-rescue

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-biomarker-neurogranin-synapse-rescue
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-12c306c9a8aa
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-biomarker-neurogranin-synapse-rescue'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

83

Outgoing

106

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Neurogranin-Guided Synapse Rescue Therapy

Neurogranin-Guided Synapse Rescue Therapy

Executive Summary

Neurogranin Biology and Synaptic Function

Molecular Mechanism

Neurogranin-Guided Synapse Rescue Therapy

Executive Summary

Neurogranin Biology and Synaptic Function

Molecular Mechanism

Expression Patterns

Neurogranin as Biomarker for Synaptic Health

Cerebrospinal Fluid Biomarker

Plasma Neurogranin

Comparison with Other Synaptic Biomarkers

Synaptic Rescue Mechanism Evidence

Therapeutic Rationale

Preclinical Evidence

Intervention Candidates and Evidence Levels

Tier 1: High Evidence Interventions

Tier 2: Moderate Evidence Interventions

Tier 3: Emerging Strategies

Implementation Roadmap

Phase 1: Biomarker Validation (12 months)

Phase 2: Target Validation (18 months)

Phase 3: Clinical Trials (24-36 months)

Phase 4: Commercialization (12 months)

Rubric Scoring (10 Dimensions)

Strategic Advantages

Differentiated Mechanism

Combination Therapy Potential

Companion Diagnostic

Risk Assessment

Technical Risks

Commercial Risks

Overview

See Also

External Links

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Grant Targets

Rubric Score

Related Pages

Cross-Links

Diseases

Mechanisms

Proteins & Genes

Cell Types

Brain Regions

Treatments

Additional Topics

References

Pathway Diagram

💬 Discussion